Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Turn Therapeutics Inc.NASDAQ: TTRX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents of $11.22M in Q1 FY2026
Q1 FY2026 cash & equivalents was $11.22M.
Context
- Cash & equivalents amounted to 60.2% of total assets at the end of Q1 FY2026.
- Cash & equivalents increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 5.08M USD
- Year-over-year change
- +481.7%
- 2-year CAGR
- +107.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.08M | +481.7% |
| FY2024 | 2024-12-31 | 872.6K | -26.1% |
| FY2023 | 2023-12-31 | 1.18M | — |
Cash & Equivalents vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 cash & equivalents of $11.22M is the 6th highest of the 9 companies compared; the peer median is $33.06M.
- Cash & equivalents amounts to 60.2% of total assets for TTRX, versus a peer median of 24.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | Mar 2026 | $59.96M | +43.5% | +1.9% | 89.8% |
| Mar 2026 | $49.57M | -32.5% | +168.5% | 28.6% | |
| Mar 2026 | $47.32M | -9.8% | -3.9% | 17.4% | |
| Mar 2026 | $35M | +89.3% | -74.4% | 18.8% | |
| Mar 2026 | $31.13M | +89.5% | -4.0% | 86.1% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $11.22M | — | — | 60.2% |
| Mar 2026 | $10.51M | +282.0% | — | 100.0% | |
| Mar 2026 | $6.3M | +1.3% | -36.7% | 21.2% | |
| Apr 2026 | $1.48M | -22.7% | -53.5% | 9.9% | |
| Peer median (excluding TTRX) | $33.06M | +22.4% | -4.0% | 24.9% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.